CN100387298C - 疫苗组合物 - Google Patents

疫苗组合物 Download PDF

Info

Publication number
CN100387298C
CN100387298C CNB038162822A CN03816282A CN100387298C CN 100387298 C CN100387298 C CN 100387298C CN B038162822 A CNB038162822 A CN B038162822A CN 03816282 A CN03816282 A CN 03816282A CN 100387298 C CN100387298 C CN 100387298C
Authority
CN
China
Prior art keywords
bleb
vaccine
pora
meningococcal
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038162822A
Other languages
English (en)
Chinese (zh)
Other versions
CN1668329A (zh
Inventor
R·F·巴伯拉莫拉勒斯
P·M·德斯芒司
F·J·多明戈奥瓦乐兹
J·普尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTITUTO FINLAY CENTRO DE INVESTIGACION-PRODUCCION DE VACUNAS Y SUEROS
GlaxoSmithKline Biologicals SA
Original Assignee
INSTITUTO FINLAY CENTRO DE INVESTIGACION-PRODUCCION DE VACUNAS Y SUEROS
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSTITUTO FINLAY CENTRO DE INVESTIGACION-PRODUCCION DE VACUNAS Y SUEROS, GlaxoSmithKline Biologicals SA filed Critical INSTITUTO FINLAY CENTRO DE INVESTIGACION-PRODUCCION DE VACUNAS Y SUEROS
Publication of CN1668329A publication Critical patent/CN1668329A/zh
Application granted granted Critical
Publication of CN100387298C publication Critical patent/CN100387298C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNB038162822A 2002-06-13 2003-06-10 疫苗组合物 Expired - Fee Related CN100387298C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation
GB0213622.4 2002-06-13

Publications (2)

Publication Number Publication Date
CN1668329A CN1668329A (zh) 2005-09-14
CN100387298C true CN100387298C (zh) 2008-05-14

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038162822A Expired - Fee Related CN100387298C (zh) 2002-06-13 2003-06-10 疫苗组合物

Country Status (20)

Country Link
US (1) US20060110412A1 (cg-RX-API-DMAC7.html)
EP (1) EP1565211A2 (cg-RX-API-DMAC7.html)
JP (1) JP2005531614A (cg-RX-API-DMAC7.html)
KR (1) KR20050049431A (cg-RX-API-DMAC7.html)
CN (1) CN100387298C (cg-RX-API-DMAC7.html)
AR (1) AR040204A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003236734A1 (cg-RX-API-DMAC7.html)
BR (1) BR0311777A (cg-RX-API-DMAC7.html)
CA (1) CA2488782A1 (cg-RX-API-DMAC7.html)
CL (1) CL2003001192A1 (cg-RX-API-DMAC7.html)
CU (1) CU23552A1 (cg-RX-API-DMAC7.html)
GB (1) GB0213622D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04012568A (cg-RX-API-DMAC7.html)
NO (1) NO20050132L (cg-RX-API-DMAC7.html)
NZ (1) NZ560766A (cg-RX-API-DMAC7.html)
PE (1) PE20040562A1 (cg-RX-API-DMAC7.html)
RU (1) RU2005100509A (cg-RX-API-DMAC7.html)
UY (1) UY27843A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003105890A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200409547B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
JP5792920B2 (ja) * 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
SI2097102T1 (sl) 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
CN101952728B (zh) * 2008-02-01 2016-05-11 圣诺菲·帕斯图尔有限公司 用于诊断肺炎链球菌的试验
SI2268618T1 (sl) 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
EP2486940B1 (en) * 2009-10-08 2017-10-04 Aeon Medix Inc. Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
KR20120107121A (ko) * 2009-12-22 2012-09-28 사노피 파스퇴르 리미티드 면역원성 조성물
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
HUE040658T2 (hu) * 2010-04-07 2019-03-28 California Inst Of Techn Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
CN116670157A (zh) * 2020-10-23 2023-08-29 Omvax公司 用于抗淋病奈瑟球菌的疫苗接种的组合物和方法
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1272062A (zh) * 1997-07-17 2000-11-01 北美疫苗公司 含有b组脑膜炎球菌膜孔蛋白和流感嗜血菌多糖的免疫偶联物
WO2001009350A2 (en) * 1999-08-03 2001-02-08 Smithkline Beecham Biologicals S.A. Genetically engineered bleb vaccine
WO2002009643A2 (en) * 2000-07-27 2002-02-07 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1272062A (zh) * 1997-07-17 2000-11-01 北美疫苗公司 含有b组脑膜炎球菌膜孔蛋白和流感嗜血菌多糖的免疫偶联物
WO2001009350A2 (en) * 1999-08-03 2001-02-08 Smithkline Beecham Biologicals S.A. Genetically engineered bleb vaccine
WO2002009643A2 (en) * 2000-07-27 2002-02-07 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Development of vaccines against meningococcal disease.. Jodar L, et al.The Lancet,Vol.359 No.9316. 2002
Development of vaccines against meningococcal disease.. Jodar L, et al.The Lancet,Vol.359 No.9316. 2002 *
Differences in surface expression of NspA amongNeisseria meningitidis group B strains.. Moe GR, et al.Infection and Immunity,Vol.67 No.11. 1999
Differences in surface expression of NspA amongNeisseria meningitidis group B strains.. Moe GR, et al.Infection and Immunity,Vol.67 No.11. 1999 *

Also Published As

Publication number Publication date
UY27843A1 (es) 2003-12-31
CA2488782A1 (en) 2003-12-24
BR0311777A (pt) 2005-03-29
MXPA04012568A (es) 2005-09-21
WO2003105890A2 (en) 2003-12-24
KR20050049431A (ko) 2005-05-25
PE20040562A1 (es) 2004-10-19
RU2005100509A (ru) 2006-06-10
AU2003236734A1 (en) 2003-12-31
EP1565211A2 (en) 2005-08-24
CU23552A1 (es) 2010-07-20
NO20050132L (no) 2005-02-11
JP2005531614A (ja) 2005-10-20
US20060110412A1 (en) 2006-05-25
AR040204A1 (es) 2005-03-16
ZA200409547B (en) 2006-07-26
NO20050132D0 (no) 2005-01-11
CL2003001192A1 (es) 2005-01-07
GB0213622D0 (en) 2002-07-24
CN1668329A (zh) 2005-09-14
NZ560766A (en) 2009-09-25
WO2003105890A3 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
US20060110412A1 (en) Vaccine composition
TWI360424B (en) Vaccine
JP5275983B2 (ja) ワクチン
US9567377B2 (en) Immunogenic composition
Zollinger et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine
JP2015521595A (ja) 血清群x髄膜炎菌のためのワクチン
RU2244749C2 (ru) Композиция для лечения или профилактики инфекции, вызванной бактерией neisseria

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080514

Termination date: 20130610